1,723 research outputs found
An In Vitro Pilot Fermentation Study on the Impact of Chlorella pyrenoidosa on Gut Microbiome Composition and Metabolites in Healthy and Coeliac Subjects
No full text© 2021 C. van der Linde, M. Barone, S. Turroni, P. Brigidi, E. Keleszade, J. Swann, A. Costabile. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0
Vibrational Density Matrix Renormalization Group
No full textVariational approaches for the calculation of vibrational wave functions and energies are a natural route to obtain highly accurate results with controllable errors. Here, we demonstrate how the density matrix renormalization group (DMRG) can be exploited to optimize vibrational wave functions (vDMRG) expressed as matrix product states. We study the convergence of these calculations with respect to the size of the local basis of each mode, the number of renormalized block states, and the number of DMRG sweeps required. We demonstrate the high accuracy achieved by vDMRG for small molecules that were intensively studied in the literature. We then proceed to show that the complete fingerprint region of the sarcosyn-glycin dipeptide can be calculated with vDMRG
Il Barone rampante di Italo Calvino visto da Marco Belpoliti. Un capolavoro a sessant’anni dalla pubblicazione
No full textThe aim of this essay is to give an explanation of a novel by Italo Calvino, Il Barone
rampante. The work is set on a previous written entitled L’occhio di Calvino by Marco
Belpoliti. That will afford us to have an analysis of the author related to his historical
context
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis
No full textRole of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.
GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group1, Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Tsuburaya A, Van Cutsem E, Buyse M.
Collaborators (54)
Buyse M, Michiels S, Oba K, Paoletti X, Rougier P, Yamamoto S, Nakamura K, Bang YJ, Bleiberg H, Burzykowski T, Buyse M, Delbaldo C, Michiels S, Morita S, Oba K, Ohashi Y, Paoletti X, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Ajani J, Boku N, Barone C, Borner M, Bouche O, Bugat R, Coombes C, Cullinan S, Dank M, Douglass H, Fuse N, Glimelius B, Hawkins R, Kanzler S, Koizumi W, Kim TW, Lordick F, Moehler M, Nio Y, Ohtsu A, Pozzo C, Reichardt P, Roth A, Schumacher C, Shitara K, Thuss-Patience P, Tsuburaya A, Van Cutsem E, Vanhoefer U, Wils J, Yamamura Y.
Author information
Abstract
We conducted an individual-patient-data meta-analysis of the efficacy of chemotherapy on overall survival (OS) and progression-free survival (PFS) in advanced/recurrent gastric cancer (AGC). Our primary research question was whether the experimental arms of the trials included in the meta-analysis showed a benefit as compared with their corresponding control arms. MEDLINE (up to 2010), Cochrane Central Register of Controlled Trials, National Institutes of Health (NIH) trial registry and proceedings of major oncologic and gastrointestinal cancer meetings were searched. Randomised controlled trials for AGC closed to patient accrual before the end of 2006 were eligible. As of December 2010, individual patient data were available from 22 trials (4245 patients, representing 47% of the targeted data) of 55 eligible trials. The overall comparison of experimental arms with the corresponding control arms showed statistically significant differences in terms of both OS and PFS. Hazard ratio was 0.88 (95% confidence interval 0.82-0.94, P<0.0001) for OS and 0.81 (0.76-0.88, P<0.0001) for PFS. The results of the sub-analysis of adding a given chemotherapeutic agent to any chemotherapy confirm the results of the overall analysis, with a hazard reduction of 11% for OS (P<0.01) and 26% for PFS (P<0.0001). This meta-analysis of individual patient data shows that the additions of experimental chemotherapeutic agents to pre-existing control or standard regimens have produced a modest improvement in OS and PFS. Median survival remained below 1 year for all investigated chemotherapy regimens and none emerged as a clear standard
Untethering an unusual cause of kidney injury in a teenager with Down syndrome
No full textAcute kidney injury (AKI) is characterized by the acute nature and the inability of kidneys to maintain fluid homeostasis as well as adequate electrolyte and acid-base balance, resulting in an accumulation of nitrogenous waste and elevation of serum blood urea nitrogen and creatinine values. Acute kidney injury may be a single isolated event, yet oftentimes, it results from an acute chronic kidney disease. It is critical to seek out the etiology of AKI and to promptly manage the underlying chronic kidney disease to prevent comorbidities and mortality that may ensue. We described a case of a 16-year-old adolescent girl with Down syndrome who presented with AKI and electrolyte aberrance.Abdominal and renal ultrasounds demonstrated a significantly dilated bladder as well as frank hydronephrosis and hydroureter bilaterally. Foley catheter was successful in relieving the obstruction and improving her renal function. However, a magnetic resonance imaging was pursued in light of her chronic constipation and back pain, and it revealed a structural defect (tethered cord) that underlies a chronic process that was highly likely contributory to her AKI. She was managed accordingly with a guarded result and required long-term and close monitoring.Peer reviewed
Measuring and modelling the nutrients residual load from the combined sewer of the eastern shore of Lake Iseo
No full textBarone, Tom, Aesthetics, Politics, and Educational Inquiry: Essays and Examples. New York: Peter Lang, 2000.
No full textReprints 14 essays by the author (organized around the influences of Eisner, Dewey, Rorty, Sarte, and Bakhtin) describing and demonstrating the use of narrative inquiry in education
Barone, Tom, Researching, Writing, and Reading Narrative Studies: Issues of Epistemology and Method, pp. 149-180 in Tom Barone, Teaching Eternity: The Enduring Outcomes of Teaching. New York: Teachers College Press, 2001.
No full textDiscusses issues involved in doing aesthetic, narrative, postmodern research such as exemplified in the author\u27s study in this volume
La vittima e il carnefice: The Portage to San Cristόbal of A.H. di George Steiner e Christopher Hampton
No full textIl romanzo “The Portage to San Cristόbal of A.H.” di George Steiner (1981), da cui deriva l’omonimo adattamento teatrale di Christopher Hampton (1983), affronta il tema della complicità fra vittime e carnefici
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine
No full textChristopher Barone, Shaymaa S Mousa, Shaker A MousaThe Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USAAbstract: Some of the most commonly prescribed medications are those for cardiovascular maladies. The beneficial effects of these medications have been well documented. However, there can be substantial variation in response to these medications among patients, which may be due to genetic variation. For this reason pharmacogenomic studies are emerging across all aspects of cardiovascular medicine. The goal of pharmacogenomics is to tailor treatment to an individual&rsquo;s genetic makeup in order to improve the benefit-to-risk ratio. This review examines the potential pharmacogenomic parameters which may lead to a future of personalized medicine. For example, it has been found that patients with CYP2C9 and VKORC1 gene variations have a different response to warfarin. Other studies looking at &beta;-blockers, ACE inhibitors, ARBs, diuretics and statins have shown some results linking genetic variations to pharmacologic response. However these studies have not impacted clinical use yet, unlike warfarin findings, as the small retrospective studies need to be followed up by larger prospective studies for definitive results.Keywords: cardiovascular, pharmacogenomics, genetics, cardiovascular medicine, personalized medicine, polymorphis
- …
